Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SH, hereinafter referred to as "Baiyunshan") released its 2025 annual report and 2026 first-quarter report simultaneously in late April 2026. This marks the first financial report card presented under the leadership of Chairman Li Xiaojun, who assumed the role in early 2025.
On the surface, this major Southern traditional Chinese medicine (TCM) company maintained growth momentum. Full-year 2025 revenue increased by 3.55% year-over-year, while net profit attributable to shareholders rose by 5.21%. However, a closer examination of this seemingly stable report reveals a different picture. The company reported losses in the fourth quarter for two consecutive years, with the loss amount widening. Its core high-margin businesses are contracting across the board. Operating cash flow showed a significant net outflow. A sharp increase in short-term debt has created a situation where available cash cannot cover these obligations. These stark facts are puncturing the bubble of Baiyunshan's "scale growth."
Chairman Li Xiaojun's challenges likely extend beyond immediate difficulties. This is no longer a simple performance fluctuation but a predicament caused by poor operational efficiency and an imbalanced debt structure. Issues at the business level are likely to persist for some time.
**1. Inflated Profitability: Profit Growth Relies on Cost-Cutting and Investments; Consecutive Fourth-Quarter Losses for Two Years**
In 2025, under new Chairman Li Xiaojun, Baiyunshan achieved operating revenue of 77.656 billion yuan and net profit attributable to shareholders of 2.983 billion yuan, a year-over-year increase of 5.21%. However, this growth is not as solid as it appears.
Quarterly profit distribution is highly unhealthy. According to segmented quarterly data in the annual report, Baiyunshan incurred a net loss attributable to shareholders of 327 million yuan in Q4 2025. After deducting non-recurring gains and losses, the loss reached 506 million yuan. This is not an isolated incident; the company also reported a loss of 323 million yuan in Q4 2024. Consecutive substantial losses in the traditional peak sales season of Q4 for two years indicate a structural crack in the company's profit foundation. Issues such as year-end impairment provisions and concentrated expense recognition are continuously eroding profits.
Furthermore, profit growth did not stem from improved cash-generating capabilities of core operations but rather from internal "belt-tightening." The annual report shows that in 2025, Baiyunshan's selling expenses, administrative expenses, and financial expenses increased by 3.69%, 4.20%, and 635.66% year-over-year, respectively. Under pressure from rising costs, the company chose to slash R&D spending. R&D expenses decreased from 764 million yuan in 2024 to 662 million yuan in 2025, a drop of 13.37%. This single "cost-saving" measure freed up approximately 100 million yuan on the books.
Simultaneously, investment income surged by 59.36% year-over-year to 469 million yuan, most of which came from interest income on term deposits and large-denomination certificates of deposit. In other words, Baiyunshan's 2025 profit growth primarily relied on cutting future-competitiveness R&D investments and financial investment returns for "cost reduction and efficiency improvement," rather than substantive improvements in drug or beverage sales.
More alarmingly, the company's year-over-year growth in net profit after deducting non-recurring gains and losses was only 0.29% for 2025, far below the 5.21% growth in net profit attributable to shareholders. The difference of approximately 620 million yuan between the two was largely filled by non-recurring items. Once investment returns fluctuate or government subsidies decrease, Baiyunshan's income statement may face genuine embarrassment.
Performance in the first quarter of this year showed little improvement. Revenue for January-March was 23.278 billion yuan, a slight increase of 3.58% year-over-year, while net profit attributable to shareholders was 1.784 billion yuan, a decrease of 2.06% year-over-year.
From the lack of substance in the full-year 2025 performance to stagnant revenue growth and declining net profit at the end of Q1 2026, the burden on Chairman Li Xiaojun's shoulders is undoubtedly heavy.
**2. Cash Flow Issues Demand Urgent Attention: High Accounts Receivable Nearing 20 Billion; Available Cash Insufficient to Cover Short-Term Debt**
If the income statement can be adjusted through measures like "cost reduction and efficiency improvement," the cash flow statement directly exposes Baiyunshan's stark reality.
For the full year 2025, net cash flow from operating activities turned negative, deteriorating sharply from a net inflow of 3.442 billion yuan in 2024 to a net outflow of 232 million yuan, a year-over-year plunge of 106.75%.
The situation did not improve entering Q1 2026. Although the quarterly report shows net operating cash flow was -2.218 billion yuan, a 43.10% improvement year-over-year, this is only because the base in the same period of 2025 was even lower (-3.897 billion yuan). Negative operating cash flow for multiple consecutive quarters indicates that the self-sustaining cash generation capability of Baiyunshan's core business is under pressure.
A key reason for this situation is accounts receivable reaching new highs. At the end of 2025, Baiyunshan's accounts receivable balance had reached 16.849 billion yuan. By the end of Q1 2026, this figure soared to 19.895 billion yuan, approaching the 20 billion yuan mark, an increase of 18.1% from the end of the previous year. Meanwhile, the inventory balance remained high at 12.469 billion yuan. These two items together tie up over 32 billion yuan in working capital, severely squeezing liquidity.
Concurrently, Baiyunshan's contract liabilities (advances from distributors) shrank dramatically. Contract liabilities were 2.833 billion yuan at the end of 2025 but fell to 1.297 billion yuan by the end of Q1 2026, a decrease of over 1.5 billion yuan in just three months. This indicates a decline in distributors' willingness to make advance payments and foreshadows significant pressure on revenue growth in the coming quarters.
Against the backdrop of weakened cash generation, Baiyunshan has had to rely heavily on borrowing to maintain operations. At the end of Q1 2026, the company's short-term borrowings climbed to 11.815 billion yuan, an increase of 23.6% from the end of 2025. Additionally, there are 1.4 billion yuan in non-current liabilities due within one year. Combined, Baiyunshan faces over 13.2 billion yuan in debt maturing within a year.
However, the company's book cash and cash equivalents decreased from 14.940 billion yuan at the end of 2025 to 12.328 billion yuan. A simple calculation shows that available cash can no longer cover short-term borrowings, indicating a liquidity gap. Meanwhile, Baiyunshan's asset-liability ratio increased from 52.57% at the end of 2025 to 53.33% at the end of Q1 2026, indicating rising financial leverage.
Currently, Chairman Li Xiaojun faces not only declining performance but also the liquidity risk posed by rapidly rising accounts receivable tying up company funds and high short-term debt that available cash cannot cover. The challenges are multiple: he must manage operations, improve collections, and secure financing. The burden on his shoulders is likely even heavier.
**3. Core Business Contraction: High-Margin Products "Losing Speed"; Wanglaoji Growth Lacks Momentum**
Setting aside financial concerns, Baiyunshan's operational foundation is also worrying. As a company focused on pharmaceuticals and health products, its high-margin business segments regressed comprehensively in 2025.
The annual report shows that Baiyunshan's modern TCM business revenue decreased by 6.54% year-over-year in 2025, chemical drug technology business revenue fell by 4.13%, and natural beverages (primarily Wanglaoji herbal tea) business revenue declined by 0.34%. None of the three high-margin core businesses grew. The only segment supporting overall revenue was the low-margin pharmaceutical commerce business, with revenue growing 6.21% year-over-year. However, this segment's gross margin is only 5.87%, a typical case of "increasing revenue without increasing profit."
The decline is more pronounced for specific star products:
* Men's health drug "Jinge" (Sildenafil Citrate Tablets): As a major profit contributor in the chemical drug segment, its sales volume decreased by 9.08% year-over-year in 2025, and operating revenue plummeted by 26.18%. This marks the second consecutive year of decline in both sales volume and revenue for this product, indicating its market moat is narrowing rapidly due to increased competition from similar products and the impact of centralized procurement policies. * Xiaochaihu Granules: Sales volume decreased by 19.59% year-over-year, and revenue fell by 19.75%, showing a clear downward trend. * Cefuroxime Sodium for Injection: Affected by the expiration of national centralized procurement follow-up bidding and intensified competition, sales volume sharply decreased by 25.85%, and revenue plunged by 30.01%.
Although a few products like Xiaoke Pills recorded growth, their scale is far from sufficient to offset the losses from core major products. Baiyunshan finds itself in an awkward position: it is continuously losing market share for high-margin branded drugs, while its low-margin distribution business grows larger. This has led to a further decline in the company's overall gross margin from 16.57% in 2024 to 16.12% in 2025, and the net profit margin also dropped from 3.78% to 3.71%.
More concerning for investors is that while competitors are increasing R&D investment to focus on innovative drugs, Baiyunshan is moving in the opposite direction by cutting R&D expenses. In 2025, R&D investment accounted for only 3.67% of its industrial main business income, with an extremely low capitalization rate. The number of R&D personnel also decreased from 688 the previous year to 624. Cutting R&D investment may beautify the income statement in the short term, but in the long run, it undoubtedly undermines the company's product competitiveness and future growth potential.
**4. Capital Operations and Internationalization: Grand Narratives vs. Harsh Reality**
Faced with a downturn in its core business, Baiyunshan has attempted to paint a new story through capital operations and internationalization. In 2025, the company acquired an 11.04% stake in Nanjing Pharmaceutical through the Guangyao Phase II Fund and participated in establishing several industrial funds. However, these investments have not only failed to contribute to performance in the short term but have also further tied up already tight funds.
The annual report shows that net cash outflow from investing activities was as high as 4.007 billion yuan in 2025, primarily used for purchasing large-denomination certificates of deposit and external investments. This reflects Baiyunshan's increasing tendency to be "distracted from its main business"—rather than investing in R&D and innovation, it prefers to put idle funds (even borrowed money) into financial management to earn interest spreads (Baiyunshan explained the year-over-year increase in net cash flow from investing activities as due to increased recovery of matured bank term deposits and large-denomination certificates of deposit by the company and its subsidiaries compared to the previous period). However, this model heavily relies on a stable interest rate environment. Once market interest rates fall (the company's financial expenses surged 635.66% precisely due to reduced interest income), it can backfire on profits.
As for internationalization, the annual report mentions progress such as Wanglaoji launching new brand identities in multiple overseas countries and Angong Niuhuang Wan obtaining registration certificates in Vietnam. But the data tells a different story: for the full year 2025, Baiyunshan's total revenue from Hong Kong, Macau, and overseas was only 294 million yuan, accounting for less than 0.4% of main business revenue. The so-called "going global" strategy is almost negligible in the current revenue structure and is far from capable of offsetting the decline in domestic business.
Thus, it appears that Baiyunshan under Chairman Li Xiaojun's leadership is facing a dilemma of "the larger the scale, the more problems arise." On one hand, revenue barely maintains growth, relying on low-profit commercial distribution business to "keep up appearances." On the other hand, core high-margin products are retreating across the board, while high accounts receivable and inventory devour cash flow. The company is forced to increase debt to supplement cash flow, but the surge in short-term debt has caused liquidity risk to rise sharply.
If Chairman Li Xiaojun cannot improve operational efficiency and achieve genuine product innovation breakthroughs in the short term, this former TCM leader may face even more severe tests.